Variant Bio, a leading genomics-driven drug discovery company, announced today it is entering a new, multi-year research collaboration with pharmaceutical
Read more
Insitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read more
AI firm Generate:Biomedicines announced on Tuesday that it has secured a $1B+ collaboration with Novartis to advance AI-driven protein therapeutics.
Read more
Sangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read more
Takeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read more
The Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read more
French biotech Medincell announced on Tuesday entering into a collaboration with AbbVie, to co-develop up to six innovative long-acting injectable
Read more
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read more
Bristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read more
American multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read more